Hemophilia A Research Program

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorUniversity of Washington

About this trial

This study longitudinally observes the intergenerational (mother-child) continuum in hemophilia A from pregnancy through early childhood. Because the study follows mother-child pairs, the study includes both a maternal cohort and a pediatric cohort. Each cohort has a primary goal: for the mother with a severe hemophilia genotype, the overarching primary goal is to understand the risks for pregnancy-associated bleeding and postpartum hemorrhage (PPH); for the child, the overarching primary goal is to understand the risks, timing, and circumstances of development of anti-FVIII antibodies. From a longitudinal perspective, risks for both bleeding in the mother and anti-FVIII antibody development in the child are expected to be influenced over time by genetic and environmental factors that begin early in (or before) pregnancy. Enrollment of blood relatives is offered to improve power to better understand inherited contributions to bleeding and inhibitor development in the mother-baby pairs.

Eligibility criteria

Qualifiers

Currently pregnant and prior to 37 weeks gestation

Known to have or at-risk of having a severe hemophilia A genotype

Pregnant with at least one fetus at-risk of inheriting severe hemophilia A

Ability to understand and willingness to provide informed consent

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

500 Participants
are grouped into 3 trial groups

Sponsors and collaborators

University of Washington

Lead sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator

RTI International

Collaborator

Emory University

Collaborator